Navigation Links
Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
Date:6/3/2008

Dr. Irene Ghobrial of the Dana-Farber Cancer Institute presents phase 2 results demonstrating the single agent clinical activity of perifosine in

patients with relapsed / refractory Waldenstroms Macroglobulinemia

NEW YORK, June 3 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that phase 2 results of perifosine (KRX-0401) in patients with relapsed/refractory Waldenstroms macroglobulinemia (WM) was presented at the 44th Annual Meeting of the American Society of Clinical Oncology. In a poster presentation held earlier today, Dr. Irene Ghobrial, Instructor of Medicine at the Dana-Farber Cancer Institute (DFCI) in Boston, MA, discussed the phase 2 results on the single agent clinical activity of perifosine in patients with both relapsed and/or refractory Waldenstroms macroglobulinemia. The presentation was entitled:

Abstract 8546: A PHASE II TRIAL OF THE NOVEL ORAL AKT INHIBITOR PERIFOSINE (KRX-0401) IN RELAPSED AND/OR REFRACTORY WALDENSTROMS MACROGLOBULINEMIA (WM).

Thirty-seven patients (median age 65 yrs) with advanced WM (76% had at least two prior treatments) were enrolled, with most patients (>75%) previously treated with at least one course of therapy on rituximab. All patients were scheduled to receive 150 mg of perifosine daily in a 28 day cycle for at least 6 cycles. Toxicities were generally well managed and tolerated with Grade 1 & 2 GI related toxicities occurring in 30% of the patients. Thirty-six patients were evaluable for response, assessed by criteria established at the second consensus panel for WM, with results as follows:

Response N Median Duration of Therapy(wks)

Partial Response 2(5%)
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
2. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
3. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
4. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
5. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
6. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
7. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
10. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
11. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... 2014 Animal Emergency Critical Care, a LifeCentre partner practice, located ... is the first in Loudoun County ... Dr. Susan M. Barnes , Medical Director, is a well-seasoned ... Cole Taylor , are avid scuba divers. "As altitude skiers ...
(Date:1/14/2014)... 14, 2014 NineSigma , Inc., the leading ... Innovation Leadership Summit , May 14-16, 2014 at the ... Ohio . This is the ... to breakthrough achievements through open innovation. Participants will learn ...
(Date:1/14/2014)... , January 14, 2014 ... Transfer Devices (CSTD) for hazardous drugs, today announced that it ... fourth straight year.   Equashield,s closed ... technicians, pharmacists, nurses and other medical professionals who ...
Breaking Medicine Technology:Hyperbaric Veterinary Medicine (hvm) Announces Animal Emergency Critical Care Installs A Small Animal Hyperbaric Chamber 2Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 2Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 3Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 4Equashield's Sales Grow by 60% in 2013 2
...  Merrimack Pharmaceuticals, Inc. announced today that the first ... clinical study combining MM-121, a fully human monoclonal ... irinotecan (Camptosar®) in patients with advanced cancers. ... The Phase 1 study evaluates the safety and ...
... Md., Dec. 13, 2011 The U.S. Food and ... device intended to aid in the detection of life-threatening ... spectroscopy. (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ) ... health care providers identify patients with critical head injuries ...
Cached Medicine Technology:Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121 in Combination with Cetuximab and Irinotecan in Patients with Advanced Cancers 2FDA Permits Marketing of the First Hand-Held Device To Aid in the Detection of Bleeding In The Skull 2FDA Permits Marketing of the First Hand-Held Device To Aid in the Detection of Bleeding In The Skull 3
(Date:4/23/2014)... Parents and physicians concerned about an increase in ... can breathe a sigh of relief. According to a ... years worth of data from states with and without ... to increased use among adolescents. The study is published ... of Adolescent Health . , "Any time a ...
(Date:4/23/2014)... that proliferation of endogenous neural precursor cells cannot ... axons. From the perspective of neural plasticity, Dr. ... in China observed the effects of functional electrical ... and expression of basic fibroblast growth factor and ... the infarct side. The researchers found that functional ...
(Date:4/22/2014)... FDA-approved device has been shown to reduce seizures in ... percent. When coupled with an innovative electrode placement planning ... the complete elimination of seizures in nearly half of ... trials. , That,s good news for a large portion ... with epilepsy whose seizures can,t be controlled with medications ...
(Date:4/22/2014)... 15 percent of all lung cancers are small ... often develop resistance to chemotherapy. However, researchers at ... new insights into the mechanisms leading to this ... , Chemotherapies work primarily by mediating B-cell lymphoma ... regulating cell death. Depending on their function, this ...
(Date:4/22/2014)... mice and rabbits, Johns Hopkins scientists have found a ... successfully preventing the development of atherosclerosis, the main cause ... of death among humans. The condition develops when fat ... stiff, narrowed and hardened, greatly reducing their ability to ... brain. , In a series of experiments, described April ...
Breaking Medicine News(10 mins):Health News:RI Hospital physician: Legalizing medical marijuana doesn't increase use among adolescents 2Health News:Newly approved brain stimulator offers hope for individuals with uncontrolled epilepsy 2Health News:Scientists pinpoint protein that could improve small cell lung cancer therapies 2Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 2Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 3Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 4
... Community Unites Behind Extraordinary Global Effort, ... SAN FRANCISCO, July 23 The Medpedia ... largest collaborative online,encyclopedia of medicine called Medpedia. ... health professionals are now,volunteering to collaboratively build ...
... treatment and prognosis may be affected, study says , , ... or pancreatic cancer may have more lymph nodes examined ... designated comprehensive cancer centers or at hospitals that do ... study. , If too few lymph nodes are examined ...
... international scientific and professional organization of more than ... technology and science of molecular imaging and nuclear ... nuclear medicine and molecular imaging research. The awards, ... announced at SNM,s 55th Annual Meeting, held in ...
... program saves time, reduces costs and increases safety; $1000 incentive may ... ... Chapel Hill, NC (PRWEB) July 22, 2008 -- Imagine a health ... prescription into a PDA or computer, and getting immediate feedback about ...
... head and neck cancer, accurately determining how advanced the cancer ... until now. New Saint Louis University research has found ... tool to detect secondary cancers, which occur in 5 to ... study findings, which will be presented on Tuesday, July 22 ...
... body, they could lead to nonsurgical treatments , , TUESDAY, July ... valuable in efforts to develop nonsurgical treatments for spinal cord ... and Sweden. , They say it may be possible to ... to repair damaged nerve cells. , An adult,s spinal cord ...
Cached Medicine News:Health News:Medpedia Announced, World's Largest Collaborative Online Encyclopedia of Medicine and Health 2Health News:Medpedia Announced, World's Largest Collaborative Online Encyclopedia of Medicine and Health 3Health News:Medpedia Announced, World's Largest Collaborative Online Encyclopedia of Medicine and Health 4Health News:Medpedia Announced, World's Largest Collaborative Online Encyclopedia of Medicine and Health 5Health News:Medpedia Announced, World's Largest Collaborative Online Encyclopedia of Medicine and Health 6Health News:Medpedia Announced, World's Largest Collaborative Online Encyclopedia of Medicine and Health 7Health News:Medpedia Announced, World's Largest Collaborative Online Encyclopedia of Medicine and Health 8Health News:More Cancer Lymph Nodes Analyzed at Specialty Centers 2Health News:Seeding the future: SNM grants grow molecular imaging and nuclear medicine research 2Health News:Seeding the future: SNM grants grow molecular imaging and nuclear medicine research 3Health News:BCBSNC Makes Electronic Prescribing Available Statewide 2Health News:BCBSNC Makes Electronic Prescribing Available Statewide 3Health News:BCBSNC Makes Electronic Prescribing Available Statewide 4Health News:Has cancer spread? Research identifies best way to find answers so treatment can begin 2Health News:Spinal Cord Stem Cells May Act as Nerve Repair System 2
Optimal solution for normal acetabulum....
The Biopro Cox comb cup is manufactured from titanium and is porous coated on the outside of the shell. The Cox comb cup accommodates a polyethylene insert....
The Plasmacup SC satisfies two important requirements: high primary stability and a low friction bearing surface....
... The integration of Trabecular Metal ... proven implant design results in a ... not only meets surgeon demands for ... provides a wide variety of shell ...
Medicine Products: